🔗 Share this article

The first new treatments for gonorrhoea in many years are being hailed as a "major milestone" in the effort against increasingly resistant strains of the infection, according to scientists.

A Worldwide Health Concern

The sexually transmitted infection are increasing globally, with figures suggesting in excess of 82 million new cases per year. Notably increased rates are observed in the African continent and countries within the World Health Organization's Western Pacific region, which encompasses Mongolia and China to New Zealand. Within England, cases have hit a historical peak, while rates across Europe in 2023 were triple the level compared to the rates from 2014.

“The clearance of fresh medications for gonorrhoea is an critical and opportune development in the context of increasing worldwide cases, increasing antimicrobial resistance and the extremely scarce treatment choices presently on offer.”

Health officials are increasingly worried about the rise in antibiotic-resistant strains. The global health body has designated it as a "priority pathogen". Ongoing monitoring revealed that the effectiveness of standard treatments like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Recent Drugs Gain Approval

One new antibiotic, also known as Nuzolvence, was approved by the US Food and Drug Administration in recent days for treating gonorrhoea. This STI can lead to serious health problems, including the inability to conceive. Researchers believe that targeted use of this new drug will help slow the emergence of superbugs.

Another new antibiotic, created by the pharmaceutical company GSK, gained clearance in concurrent days. This treatment, which is employed against UTIs, was demonstrated in studies to be effective against superbug versions of the gonorrhoea bacteria.

A Unique Approach to Creation

This new treatment emerged from a innovative non-profit model for drug creation. The non-profit organisation GARDP worked alongside the drug firm Innoviva to see it through.

“This milestone signifies a huge turning point in the therapy of multidrug-resistant gonorrhoea, which until now has been outpacing medical innovation.”

Clinical Trial Data and Global Access

Based on findings detailed in a prominent scientific publication, zoliflodacin cured over nine in ten of genital gonorrhoea infections. This establishes an similar efficacy with the typical regimen, which uses an injection and a pill. The research included hundreds of patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its development partnership, the non-profit has the authority to license and sell the drug in many developing nations.

Medical professionals on the front lines have expressed positive views. Having a single-dose, oral treatment such as this is seen as a "revolutionary step" for gonorrhoea control. This is viewed as vital to alleviate the strain of the disease for people and to prevent the spread of highly drug-resistant gonorrhoea globally.